CPhI Worldwide 2019

Patient centricity to 'change CDMO business internally': Piramal

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/gorodenkoff)
(Image: Getty/gorodenkoff)

Related tags: Piramal, Patient centricity, Contract manufacturing, Contract manufacturing organisation

Speaking at CPhI 2019, Piramal CCO puts the spotlight on patients who ultimately 'pay the bill,' and explains how this mentality could reshape the CDMO business.

Stuart Needleman, the chief commercial officer of Piramal, was recently also appointed the newly-established title of the chief patient centricity officer, as part of the company’s attempt to “put the patient first and open up to a sustained engagement,”​ the executive said during a panel discussion at CPhI Worldwide this week in Frankfurt.

Steps in this direction, according to Needleman, are part of a ‘progressive trend’ across the industry, including a shift toward personalized medicine. 

This trend “means a new mindset and culture” ​for Piramal regarding the ‘fundamental’ objective of reducing the burden of disease and how product development and manufacture are approached.

“Initially, pharmaceutical companies are our customers, but at the end of the day, the customer is the patient. So, we have transformed the mindset to actually consider the patient as [the person] who ultimately pays us, even from a CDMO perspective,”​ Needleman noted.

Once the spotlight is put on the patient, Needleman explained that the way the contract development and manufacturing organisation (CDMO) operates, ‘changes internally.’ 

“It’s an internal mindset to make sure that you don’t go home until the job is done, and we think that this will resonate with our customers, as well as with the person paying the bill,”​ he added.

According to Piramal’s executive, this ‘mindset shift’ is something that will soon also be seen around the rest of the CDMO space.  

Moreover, under the same mindset, Piramal is having patients visiting the company, meeting with the employees and executives and talking about their journey and experiences with the drugs produced by the company. 

This process is expected to “make a difference in how Piramal behaves as an organisation, boost research, and motivate the workers,” ​Needleman added.

Finally, the executive also highlighted the need to sufficiently inform the patients, because, in the foreseeable future, it will be them that will make the decisions about their treatments and, ultimately, about how the market evolves.

Related news

Show more

Related products

show more

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars